Stock Events

Stock Events

Search...

Insmed

$71.04

55

-$1.87-2.56% Friday 20:00

Statistics

Day High

73.22

Day Low

70.19

52W High

80.53

52W Low

21.92

Volume

1,723,773

Avg. Volume

2,535,803

Mkt Cap

13.14B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

24OctExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.94

-1.65

-1.35

-1.06

Expected EPS

-1.203364

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INSM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for cystic fibrosis, a market that Insmed is targeting with its therapies.

Gilead Sciences

Gilead Sciences competes in the biopharmaceutical space, focusing on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, overlapping with Insmed's focus on serious and rare diseases.

AbbVie competes with Insmed in the area of cystic fibrosis and other serious health conditions through its robust pipeline of biopharmaceuticals.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a competitor due to its focus on developing monoclonal antibodies for the treatment of rare diseases, a similar focus area as Insmed.

AstraZeneca competes with Insmed in the respiratory disease market, including treatments for conditions like asthma and COPD.

Biogen competes in the biopharmaceutical space focusing on neurological diseases, overlapping with Insmed's interest in rare diseases.

Amgen competes with Insmed through its development of treatments for serious illnesses, including those in the respiratory and inflammation areas.

Novartis competes with Insmed in the healthcare sector, focusing on innovative medicines for various diseases, including respiratory.

Galapagos NV competes with Insmed in the development of novel modes of action for diseases with high unmet medical need, including cystic fibrosis.

Analyst Ratings

84.21$Average Price Target

The highest estimate is $102.

From 15 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Pharmaceutical Preparation Manufacturing

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Show more...

CEO

William Lewis

Employees

912

Country

US

ISIN

US4576693075

Listings